

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Duvelisib, CAS [[1201438-56-3]] FBM-10-4788

| | |
|----------------------------|----------------------------------|
| Article Name | Duvelisib, CAS [[1201438-56-3]] |
| Biozol Catalog Number | FBM-10-4788 |
| Supplier Catalog Number | 10-4788 |
| Alternative Catalog Number | FBM-10-4788-5MG,FBM-10-4788-25MG |
| Manufacturer | Focus Biomolecules |
| Category | Biochemikalien |
| Product Description | PI3K delta/gamma inhibitor... |
| Molecular Weight | 416.87 |
| Purity | 98% by HPLC NMR (Conforms) |
| Form | White solid |
| CAS Number | [1201438-56-3] |
| Formula | C22H17CIN6O |

| | |
|-------------------|---|
| Application Notes | <p>Duvelisib (1201438-56-3) is a potent and selective (IC50s: PI3Kalpha = 1602nM, PI3Kbeta = 85nM, PI3Kdelta= 2.5nM, PI3Kgamma = 27nM) dual PI3Kdelta/gamma inhibitor.¹ It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.² Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others.^{3,4} Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.⁵ Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes</p> |
|-------------------|---|